Harbour backs first registrational trials with $75M B+ round

Harbour BioMed raised $75 million in a series B+ round to advance its clinical antibody programs, including three registrational trials planned for this year.

New investors SK Holdings, Greater Bay Area Fund, Efung Capital, Zheshang Venture Capital, Zhejiang University Future Capital and JT

Read the full 433 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers